What factors drove the changes in Optimizerx's revenue and profit?

What does Optimizerx do and what are its main business segments?

What guidance did Optimizerx's management provide for the next earnings period?

What were the key takeaways from Optimizerx’s earnings call?

What is the market's earnings forecast for Optimizerx next quarter?

What were the key takeaways from Optimizerx's earnings call?

What is Optimizerx's gross profit margin?

What is the revenue and EPS growth rate for Optimizerx year over year?

- **Strong Financials**: FY2025 revenue $109.4 million, EBITDA $24.3 million; Q4 gross margin 74.8%. 
- **2026 Outlook**: Revenue $109-114 million, EBITDA $21-25 million; mid-60% gross margin target. 
- **AI and Growth**: AI-driven efficiency in content creation; DAP adoption driving multi-brand expansion. 
- **Market Trends**: Shorter contracts, MFN-related conservatism, mid-tier manufacturer growth. 
- **Share Buybacks**: $10 million program announced; debt reduction a priority.

**【CEO Summary Section】**
- **Q4 and Full-Year Results**: Revenue of $3.2 million (Q4) and $109.4 million (FY2025), exceeding expectations. Adjusted EBITDA was $12 million (Q4) and $24.3 million (FY2025). 
- **Market Dynamics**: Softness in contracted revenue due to a shift away from managed services and conservative spending amid MFN pricing negotiations. 
- **2026 Guidance**: Revenue $109-114 million, EBITDA $21-25 million. Share repurchase program announced. 
- **AI Impact**: Minimal disruption; AI may drive efficiency in content creation, benefiting OptimizeRx's execution capabilities. 
- **Customer Expansion**: Strong growth with mid-tier and long-tail manufacturers, filling infrastructure gaps for new asset launches. 

**【CFO Financial Commentary】**
- **Q4 Financials**: Gross margin 74.8% (vs. 68.1% in 2024), non-GAAP net income $9.9 million. Cash increased to $23.4 million (from $13.4 million in 2024). 
- **2026 Outlook**: Mid-60% gross margin target; expects normalization in second half. Operating cash flow $18.7 million (FY2025). 
- **Debt Management**: $26.3 million debt balance; plans to use free cash flow for debt reduction and share buybacks. 

**【Q&A Highlights】**
- **End-Market Weakness**: Broader pause across clients due to MFN negotiations, shorter contract durations (e.g., 6-month vs. 12-month). 
- **AI and DAP Adoption**: AI may reduce content creation costs, freeing budgets for execution. DAP adoption drove multi-brand scaling, e.g., $9 million+ client expansion. 
- **Customer Behavior**: Mid-tier manufacturers leveraging OptimizeRx for cost-effective commercialization, outpacing expectations. 
- **Revenue Phasing**: 40% first-half, 60% second-half; FY2025 managed services ($9 million) not expected to recur. 
- **MFN Impact**: Temporary spending conservatism expected to normalize in H2 2026. 
- **AI in Pharma**: AI streamlining clinical trials and regulatory processes, enhancing execution opportunities for OptimizeRx.

OptimizeRx Corporation(OPRX)-20260306-2025 Q4 Earnings call transcript

- **Q3 Strong Performance**: 22% revenue growth to $26.1M, EBITDA up $2M YoY. 
- **2025 Guidance Raised**: Revenue $105-109M, EBITDA $16-19M. 
- **2026 Outlook**: $118-124M revenue, EBITDA $19-22M with 5-15% new logo mix. 
- **Gross Margin Expansion**: 67.2% Q3, stable at 67%+ for 2026. 
- **Digital Shift**: 2026 RFPs up 50%, HCP/DTC balance. 
- **Debt Reduction**: $7.5M paid YTD, no equity needs. 
- **Rule of 40 Target**: Top 5 clients at $11M avg. revenue. 


**【CEO Summary Section】**
- Q3 2025 revenue: $26.1 million (22% YoY growth), adjusted EBITDA: $5.1 million (up $2 million YoY). 
- Updated 2025 guidance: Revenue $105-109 million (vs. prior $100-105M), EBITDA $16-19 million. 
- Initial 2026 guidance: Revenue $118-124 million, EBITDA $19-22 million. 
- Debt reduction: $2 million post-Q3, total 2025 paydown $7.5 million. 
- Strategic focus: Digital pharma marketing, omnichannel platform, customer retention. 
- Top 5 clients: Avg. 12M revenue YoY, Rule of 40 target in sight. 
- RFP trends: Strong 2026 pipeline, HCP/DTC balance, digital shift. 

**【CFO Financial Commentary】**
- Q3 gross margin: 67.2% (vs. 63.1% YoY), driven by product mix and scale. 
- Operating expenses: $15.5 million (down $6.5 million YoY), cash OpEx $12.4 million (up due to bonuses). 
- Non-GAAP EPS: $0.20 (vs. $0.12 YoY), cash flow $11.6 million (9M). 
- KPIs: Top 20 pharma revenue $3.1 million, net retention 120%, FTE revenue $820K. 

**【Q&A Highlights】**
- **2026 Guidance**: Contracted revenue visibility, 5-15% new logo mix. 
- **RFP Trends**: Digital/HCP/DTC balance, mid-tier pharma demand. 
- **Revenue Smoothing**: Managed services shift to subscriptive model. 
- **Gross Margin**: 67%+ stable, upside from scale. 
- **Partnership**: Lamar Advertising pilot for digital billboards. 
- **Operating Leverage**: Bonus/commission-driven OpEx growth. 


OptimizeRx Corporation (OPRX) Q3 2025 Earnings Call Transcript

- **Revenue Growth**: 55% YoY to $29.2M, with EBITDA up $5M YoY to $5.8M.
- **Debt Reduction**: $4.5M principal paid Q2, $4M above schedule; accelerating debt paydown.
- **Operational Excellence**: Flat OpEx ($15.4M) despite 55% revenue growth, driven by operational leverage.
- **Customer Focus**: Top 5 clients now average $11M annual revenue, highlighting retention and growth.
- **Digital Shift**: Pharma clients moving to efficient digital channels, aligning with OPRX's omnichannel strategy.

**【CEO Summary Section】**
- Q2 2025 revenue surged 55% YoY to $29.2 million, with adjusted EBITDA of $5.8 million, up $5 million YoY.
- Contracted revenue grew over 30% YoY, driving confidence in 2025 guidance of $104-$108 million revenue and $14.5-$17.5 million EBITDA.
- Debt reduced by $4.5 million Q2, exceeding schedule by $4 million, with plans to accelerate debt paydown using free cash flow.
- Highlighted strategic focus on operational excellence, cross-selling, and AI-driven script lift optimization.
- Top 5 customers now average $11 million annual revenue, underscoring customer retention and growth.

**【CFO Financial Commentary】**
- Gross margin improved to 63.8% (vs. 62.2% Q2 2024) due to favorable product mix and scale.
- Non-GAAP net income of $4.5 million ($0.24 EPS) vs. $0.3 million ($0.02 EPS) YoY.
- Operating cash flow of $8.4 million for H1, ending Q2 with $16.6 million cash.
- KPIs: Net revenue retention 121%, revenue per FTE $767k (vs. $658k YoY).

**【Q&A Highlights】**
- **Revenue Cadence**: Q2 included one-time managed service revenue; expect normalized growth in H2.
- **OpEx Sustainability**: Flat Q2 OpEx ($15.4 million) reflects operational leverage; no material increases expected in H2.
- **Contracted Revenue Mix**: Growth driven by mid-tier pharma companies seeking efficient digital solutions.
- **Pharma Trends**: Clients prioritizing high ROI digital channels amid regulatory uncertainty, aligning with OPRX's omnichannel platform.
- **2026 Outlook**: Consensus projections seen as achievable, with formal guidance pending RFP activity.

OptimizeRx (OPRX)-7 Aug 25-2025 Q2 Earnings call transcript

- **Revenue Growth**: Q1 2025 revenue up 11% YoY to $21.9M, with EBITDA improving $2M YoY.
- **Subscription Momentum**: 5% of 2025 revenue now subscription-based, driving long-term stability.
- **Margin Resilience**: Gross margin held steady at 60.9%, supported by cost controls and high-margin data solutions.
- **Pipeline Confidence**: >80% of 2025 guidance backed by contracted deals, with 25% YoY increase in committed backlog.
- **Client Engagement**: NRR of 114% reflects strong customer retention and upselling success.

**【CEO Opening Remarks】**
- Q1 2025 revenue increased 11% YoY to $21.9 million, with adjusted EBITDA of $1.5 million, up nearly $2 million YoY.
- Contracted revenue grew over 20% YoY, driving confidence in 2025 guidance of $101-106 million revenue and $13-15 million EBITDA.
- 5% of projected 2025 revenue converted to subscription contracts, with focus on data-driven solutions and patient engagement.
- Rule of 40 target achievable through disciplined cost management and upselling strategies.

**【CFO Financial Details】**
- Gross margin 60.9% (down 1.1% YoY due to DTC managed services mix).
- Operating expenses decreased $1.8 million YoY, driven by cost savings and lower stock-based compensation.
- Net loss narrowed to $2.2 million vs. $6.9 million YoY, with operating cash flow of $3.9 million.
- Committed backlog exceeded $70 million, up 25% YoY, with 80%+ revenue visibility.
- KPIs: NRR 114%, revenue per FTE $710k, top 20 pharma clients represent 63% of revenue.

**【Q&A Key Highlights】**
- **Market Sentiment**: No pullback from clients amid regulatory uncertainty; pharma leaning into digital channels for cost efficiency.
- **Subscription Impact**: Revenue smoothing benefits with low cost of sales; targeting multi-year contracts for future scalability.
- **Gross Margin Outlook**: Low 60% range stable, with focus on high-margin data solutions.
- **Pipeline Strength**: >80% contracted revenue; 20% remaining from pipeline execution.
- **Seasonality**: Q2 expected to show modest sequential growth, typical 35-45% of annual revenue in first half.

OptimizeRx (OPRX)-12 May 25-2025 Q1 Earnings call transcript

- **Record 2024 Performance**: $92.1M revenue (+15% YoY), $11.7M adj. EBITDA, beating all metrics.
- **DAAP Dominance**: 100% YoY new DAAP deals growth, 25% script lift, 10:1 ROI, now 30% of revenue.
- **Subscription Shift**: Targeting 60%+ reoccurring revenue by 2025 via DAAP data subscription model.
- **Rule of 40 Roadmap**: 3-5 year goal with 70% EBITDA expansion, 30% top-line growth.
- **2025 Momentum**: Q1 up 20% YoY, full year DAAP >100% growth, 121% net retention.


**【CEO Summary Section】**
- Fiscal 2024 revenue reached $92.1 million, exceeding guidance and Street expectations, with adjusted EBITDA of $11.7 million.
- Emphasis on becoming a Rule of 40 company through operational excellence, customer centricity, and subscription-based DAAP model conversion.
- Top 5 customers averaged $9.1 million in 2024, with plans to add at least one more to this level in 2025.
- DAAP-related revenue grew 100% YoY, driving 25% script lift and 10:1 ROI on HCP marketing spend.

**【CFO Financial Commentary】**
- Q4 2024 revenue: $32.3 million (+14% YoY), gross margin 68.2% (vs. 62.9% prior year), net loss $0.1 million (vs. $4.1 million prior year).
- Non-GAAP net income: $5.5 million ($0.30/diluted share) vs. $4.6 million ($0.26) prior year.
- Full year 2024: Top 20 pharma clients averaged $2.9 million (+22% YoY), net revenue retention 121% (vs. 105% prior year), revenue per FTE $701,000 (+19% YoY).
- Cash balance: $13.4 million, debt $34.3 million after $2.5 million principal repayment.

**【Q&A Key Themes】**
- **Customer Centricity & Subscription Model**: Shifting DAAP data component to subscription, aiming for 60%+ reoccurring revenue by 2025. Q4 2024 DAAP mix: ~30% of total revenue.
- **Gross Margin Expansion**: Q4 2024 gross margin 68.2% driven by DAAP mix; targeting 60-65% range in 2025.
- **Rule of 40 Timeline**: 3-5 year goal with ~70% contribution from EBITDA expansion, 30% from top-line growth.
- **Competitive Position**: Unique HCP + DTC integration with ~100% net revenue retention, vs. ~50% industry average.
- **2025 Outlook**: Conservative guidance with Q1 2025 revenue up 20% YoY, full year DAAP growth >100%.


Actual								-0.06	0.02	0.07	0.16	0.03	0.1	0.09	0.22	-0.01	0.04	0.07	0.25	-0.09	-0.01	0.09	0.26	-0.11	0.02	0.12	0.3	0.08	0.24	0.2	0.51
Forecast								-0.04	-0.03	0.04	0.155	0.008	0.072	0.13	0.206	-0.012	0.09	0.0338	0.2414	-0.08	-0.0214	0.025	0.3836	-0.1276	-0.0644	0.059	0.2719	-0.12	0.0167	0.0369	0.2244
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-50.00%	+166.67%	+75.00%	+3.23%	+275.00%	+38.89%	-30.77%	+6.80%	+16.67%	-55.56%	+107.10%	+3.56%	-12.50%	+53.27%	+260.00%	-32.22%	+13.79%	+131.06%	+103.39%	+10.33%	+166.67%	+1337.13%	+442.01%	+127.27%

OPRX

OPRX fundamentals

OPRX Q4 2025 Earnings

Earnings Call

You can ask Aime

OPRX

OPRX fundamentals

OPRX Q4 2025 Earnings

Earnings Call

OPRX Earnings Call Summary for Q4/20254:30 PM on Mar 5, 2026

OPRX Earnings Call Summary for Q3/20254:30 PM on Nov 6, 2025

OPRX Earnings Call Summary for Q2/20254:30 PM on Aug 7, 2025

OPRX Earnings Call Summary for Q1/20254:30 PM on May 12, 2025

OPRX Earnings Call Summary for Q4/20248:30 AM on Mar 12, 2025

You can ask Aime